Karyopharm Therapeutics Inc. Quarterly Depreciation in USD from Q1 2020 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Karyopharm Therapeutics Inc. quarterly/annual Depreciation history and growth rate from Q1 2020 to Q1 2024.
  • Karyopharm Therapeutics Inc. Depreciation for the quarter ending March 31, 2024 was $85K, a 70.7% decline year-over-year.
  • Karyopharm Therapeutics Inc. annual Depreciation for 2023 was $530K, a 14.7% decline from 2022.
  • Karyopharm Therapeutics Inc. annual Depreciation for 2022 was $621K, a 21.3% decline from 2021.
  • Karyopharm Therapeutics Inc. annual Depreciation for 2021 was $789K, a 18.8% decline from 2020.
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $85K -$205K -70.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q1 2023 $290K +$113K +63.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q1 2022 $177K -$58K -24.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q1 2021 $235K -$7K -2.89% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q1 2020 $242K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.